Summary.-Women who had used oral contraceptives, particularly long-term users, were found to have higher rates of malignant melanoma and of a past history of skin cancer than those who had never used oral contraceptives. This excess was confined to lesions of the lower limb. The association between oral contraceptive use and melanoma was noted in 3 separate sets of data, although it was statistically significant only in one. The possibility that this relationship is indirect because, for example, oral contraceptive users are more likely than never-users to be exposed to sunlight and thus to develop malignant melanoma, cannot be excluded.
HYPERPIGMENTATION, especially of the face, was one of the first reported and is one of the more common side-effects of oral contraceptive (OC) use (Cook, Gamble and Satterthwaite, 1961; Jelinek, 1970) . There is marked regional variation in the reported incidence of chloasma, it being particularly frequent in sunny climates (Jelinek, 1970; Koide and Lyle, 1975; Carruthers, 1966 Carruthers, , 1967 . Its incidence increases with duration of OC use (Carruthers, 1966) . The mechanisms of the pigmentary changes are not fully understood. Animal experiments carried out by Snell and Bischitz (1960) have shown that oestrogens and oestrogen-progestogen combinations cause an increase both in melanocyte count and also in intracellular and extracellular melanin content. Although oestrogen is a major stimulant of melanogenesis, its effect is greatly augmented by the simultaneous administration of progestogens. These effects are thought to be due to direct action of the hormones on the melanocyte, but it is also possible that the hormones act indirectly by stimulating the pituitary to secrete melanocyte-stimulating hormone.
Because of the hormonal control of pigmentation, the possibility that OC use may predispose to the development of malignant melanoma was suggested by Ellerbroek (1968) . This relationship was further investigated in a population of women who were members of the KaiserPermanente Health Plan in Walnut Creek, a suburb of the San Francisco Bay Area in California. The preliminary findings, although based on small numbers, are reported here.
STUDY POPULATION AND METHODS
The relationship of malignant melanoma to OC use was studied in two separate groups of women. In the first, Group A, incidence and mortality rates from malignant melanoma and the proportion reporting a past history of skin cancer were compared in users and nonusers of OCs. In the second, Group B, a comparison of OC use in women with malignant melanoma and in matched controls was performed.
Group A.-Between December 1968 and February 1972, 17,942 Ramcharan (1974) .
Data on the occurrence of skin cancer in this population were obtained in several ways. At entry into the study each woman was asked, along with other questions, about a past history of skin cancer. During the followup period, new cases of malignant melanoma were identified from the tumour registers of the Pathology Department in Kaiser-Permanente Medical Center, Walnut Creek. Twentytwo new cases were diagnosed, and a copy of the pathologist's report was obtained for all these.
The which records belonged to cases and controls examined a section of each record. For the cases, this section covered the period preceding any mention of a suspicious pigmented mole or melanoma; for the controls, it covered the period corresponding to that of the index case. Along with information on year of birth and parity, the clerk noted all references to OC and oestrogen use, including date of each prescription and brand used. Each woman was then coded, without knowledge of the diagnosis, as an "ever-user" or "never-user" of OCs and oestrogens or as"no information available". Seven cases and 15 controls were coded as "no information available" and direct mail or telephone contact with them was attempted. All but 2 cases and 5 controls were contacted in this way. To assess the validity of the data extracted from the medical records, a sub-sample of the study population was contacted by mail. For all but one of the 9 who replied, the reported history of OC and oestrogen use corresponded tothat which had been extracted from their records. The discrepancy arose from one case who reported that she had used OCs in the past, but she had been classified as a "never-user" according to the information in her medical records.
RESULTS
Group A. Table I shows the number of new cases of malignant melanoma diagnosed during the study period, and the incidence rates per 100,000 womanyears by age of the woman at entry to the study and by OC and oestrogen use. No melanomas were diagnosed at age 15-24. Except at age 35-44, the incidence rate of malignant melanoma was higher in OC users than never-users, especially in those who had used OCs for 4 years or more. The incidence of melanoma was also higher in oestrogen users than in neverusers. None of these differences was statistically significant. The relationships of melanoma to other factors, including parity, marital status, education, smoking habits, eye colour, a history of hypertension or diabetes and the use of tranquillizers, weight-reducing medicines, thyroid extracts or antihypertensive agents, were examined. The well-known increased risk of malignant melanoma among those with light-coloured eyes compared to those with brown eyes (Lancaster and Nelson, 1957) was apparent. But for both eye colours an increased incidence of malignant melanoma among OC users was noted. No other factors appeared to be associated with the development of melanoma.
There were 3 deaths from malignant melanoma during the study period. Two of these had been diagnosed before the women entered the study. All deaths were among OC users. A history of malignant cancer of the skin was reported by 164 women. The ageadjusted rates for those with a history of malignant tumors are shown in Table II. OC users, particularly those with a duration of use of 4 years or more, reported higher rates of malignant skin tumours. Users of oestrogens and of other hormones also reported slightly higher rates of these tum- parity. These differences were not, however, statistically significant. Table IV shows for all persons with melanoma the distribution of the site of No. cases (%) 22 (60) 13 (35) 2 (5) 37 (100) No. controls (% ) 33 (45) 36 (49) 5 (7) 74 (101) Relative risk. (Ever-users: never-users) = 1 .8: 1. the lesions, by OC and oestrogen use. Data from Groups A and B were combined in this table. The overall distribution of the lesions found in this population is similar to that reported for women in other studies (Lee and Yongehaiyudha, 1971 ). Ever-users of OCs or oestrogens showed an excess of lesions of the lower limbs.
The distribution of the type of OC, including its oestrogen and progestogen content, ever-used by those with malignant melanoma was compared with that used by those without melanoma. No clear association was found between brand of OC or its oestrogen or progestogen content and the occurrence of malignant melanoma.
DISCUSSION AND CONCLUSION
An excess of ever-users of oral contraceptives, particularly long-term OC users, was found among those with newly diagnosed malignant melanoma, and also among those with a past history of skin cancer. The association was weak, but was found in 3 separate sets of data. Only the differences in past history of skin cancer were statistically significant. Although each set of data has its inherent biases, the consistency of the findings strengthens the overall conclusion that there may be a real association between OC use and the development of malignant melanoma.
Even if an association between OC use and malignant melanoma does exist, this does not necessarily imply causality. OC users may, because of their behavioural or other personal characteristics, be especially prone to develop malignant melanoma. Lancaster and Nelson (1957) reported that those with a fair complexion, with blue, green, or grey eyes, or those who spend more than 2 hours out of doors each day are more likely to develop malignant melanoma than those with darker complexions, brown eyes or who spend less than 2 hours out of doors each day. In this study, a relationship between eye colour and melanoma incidence was also noted, but this could not explain the increased ratesfound among OCusers. Unfortunately, no measure of outdoor activity or exposure to sunlight is available in the populations studied. If the majority of those with a past history of skin cancer had developed their malignancies before OC use, this would suggest that OC ever-users and never-users differed in their susceptibility to skin cancer even before they began using OCs. Because of the higher rates in (17) Total (%) 36 (100) 5 (100) 16 (100) 2 (100) (Magnus, 1973; Elwood and Lee, 1975 (Scott, 1975) and changes in recreation activities and clothing fashion (Lee and Yongchiavudha, 1971 ) have been sUggested.
It is biologically plausible that the prolonged adnministration of hormones should affect the risk of developing malignaint melanonma. This is because of the known stimtilatorv action of oestrogens and oestrogen-progestogen combinations on melanocyte activity (Sinell and Bischitz, 1960) the finding of oestrogen receptors in malignant melanoma cells (Fisher, Neifeld and Lippman, 1976) , and the report of differential survival between parous and nulliparous women with melanoma (Hersey et al., 1977 Nelson, 1957; Cellin, Kopf and Garfinkel, 1969; Davis, Herron and McLeod, 1966) . It may be of some importance, as the recent increases in melanoma incidence among young women have been almost entirely confined to lesions of the lower limbs (Lee and Yongchaiyudha, 1971 ).
In conclusion, the observed associatioin between OC use aind maligniiant melanoma is uinlikely to be the result of diagnostic biases, but could reflect differential exposure to suinlight among OC users anid neverusers, or be a chance finding. It seems important that other relevant data should be collected from different popt)lations. 
